# IRulya Therapeutics Inc.: financial statements, quarterly

IRLA · Nasdaq · CIK 1662774 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/irla.md) · [Financials](/companies/irla/financials.md) · [Filings](/companies/irla/filings.md) · [Insiders](/companies/irla/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/irla/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [1.4](/filings/0001662774-24-000011.md) | [3.4 d](/filings/0001662774-25-000012.md) | [3.7](/filings/0001662774-25-000032.md) | [4.1](/filings/0000950170-25-106535.md) | [4.9](/filings/0001193125-25-277529.md) | [5.8 d](/filings/0001193125-26-151364.md) | [8.1](/filings/0001193125-26-217098.md) | [6.6](/filings/0001193125-26-352201.md) | [8.1](/filings/0001193125-25-277529.md) | [12.6 d](/filings/0001193125-26-151364.md) | [6.8](/filings/0001193125-26-217098.md) | [5.5](/filings/0001193125-26-352201.md) |
| Operating income | $m | [(6.1)](/filings/0001662774-24-000011.md) | [(9.9) d](/filings/0001662774-25-000012.md) | [(11.2)](/filings/0001662774-25-000032.md) | [(28.2)](/filings/0000950170-25-106535.md) | [(5.9)](/filings/0001193125-25-277529.md) | [(12.0) d](/filings/0001193125-26-151364.md) | [(14.9)](/filings/0001193125-26-217098.md) | [(10.4)](/filings/0001193125-26-352201.md) | [(13.4)](/filings/0001193125-25-277529.md) | [(19.4) d](/filings/0001193125-26-151364.md) | [(14.6)](/filings/0001193125-26-217098.md) | [(79.8)](/filings/0001193125-26-352201.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.0](/filings/0001662774-24-000011.md) | [0.1 d](/filings/0001662774-25-000012.md) | [0.0](/filings/0001662774-25-000032.md) | [0.0](/filings/0000950170-25-106535.md) | [0.0](/filings/0001193125-25-277529.md) | [0.0 d](/filings/0001193125-26-151364.md) | [0.0](/filings/0001193125-26-217098.md) | [0.1](/filings/0001193125-26-352201.md) | [(0.0)](/filings/0001193125-25-277529.md) | [3.1 d](/filings/0001193125-26-151364.md) | [(5.3)](/filings/0001193125-26-217098.md) | [0.1](/filings/0001193125-26-352201.md) |
| Net income | $m | [(5.4)](/filings/0001662774-24-000011.md) | [(8.9) d](/filings/0001662774-25-000012.md) | [(11.1)](/filings/0001662774-25-000032.md) | [(27.7)](/filings/0000950170-25-106535.md) | [(5.5)](/filings/0001193125-25-277529.md) | [(12.5) d](/filings/0001193125-26-151364.md) | [(15.0)](/filings/0001193125-26-217098.md) | [(16.0)](/filings/0001193125-26-352201.md) | [(13.4)](/filings/0001193125-25-277529.md) | [(39.5) d](/filings/0001193125-26-151364.md) | [35.9](/filings/0001193125-26-217098.md) | [(75.5)](/filings/0001193125-26-352201.md) |
| Diluted EPS | $ per share | [(0.15)](/filings/0001662774-24-000011.md) | not reported | [(0.26)](/filings/0001662774-25-000032.md) | [(0.64)](/filings/0000950170-25-106535.md) | [(0.13)](/filings/0001193125-25-277529.md) | not reported | [(3.42)](/filings/0001193125-26-217098.md) | [(68.75)](/filings/0001193125-26-352201.md) | [(0.25)](/filings/0001193125-25-277529.md) | not reported | [2.88](/filings/0001193125-26-217098.md) | [(12.31)](/filings/0001193125-26-352201.md) |
| Basic EPS | $ per share | [(0.15)](/filings/0001662774-24-000011.md) | not reported | [(0.26)](/filings/0001662774-25-000032.md) | [(0.64)](/filings/0000950170-25-106535.md) | [(0.13)](/filings/0001193125-25-277529.md) | not reported | [(3.42)](/filings/0001193125-26-217098.md) | [(68.75)](/filings/0001193125-26-352201.md) | [(0.25)](/filings/0001193125-25-277529.md) | not reported | [3.60](/filings/0001193125-26-217098.md) | [(12.31)](/filings/0001193125-26-352201.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [20.8](/filings/0000950170-23-063716.md) | not reported | not reported | not reported | not reported | [6.2](/filings/0001193125-26-151364.md) | [7.8](/filings/0001662774-25-000032.md) | [16.8](/filings/0000950170-25-106535.md) | [6.5](/filings/0001193125-25-277529.md) | [5.8](/filings/0001193125-26-352201.md) | [18.2](/filings/0001193125-26-217098.md) | [116](/filings/0001193125-26-352201.md) |
| Current assets | $m | [85.2](/filings/0000950170-23-063716.md) | [77.4](/filings/0001662774-25-000012.md) | [70.4](/filings/0000950170-24-058201.md) | [63.4](/filings/0001662774-24-000005.md) | [51.7](/filings/0001662774-24-000011.md) | [44.0](/filings/0001193125-26-151364.md) | [33.8](/filings/0001662774-25-000032.md) | [37.3](/filings/0000950170-25-106535.md) | [29.2](/filings/0001193125-25-277529.md) | [22.9](/filings/0001193125-26-352201.md) | [25.6](/filings/0001193125-26-217098.md) | [123](/filings/0001193125-26-352201.md) |
| Total assets | $m | [85.4](/filings/0000950170-23-063716.md) | [168](/filings/0001662774-25-000012.md) | [159](/filings/0000950170-24-058201.md) | [135](/filings/0001662774-24-000005.md) | [127](/filings/0001662774-24-000011.md) | [114](/filings/0001193125-26-151364.md) | [107](/filings/0001662774-25-000032.md) | [117](/filings/0000950170-25-106535.md) | [110](/filings/0001193125-25-277529.md) | [93.5](/filings/0001193125-26-352201.md) | [26.6](/filings/0001193125-26-217098.md) | [124](/filings/0001193125-26-352201.md) |
| Current liabilities | $m | [2.3](/filings/0000950170-23-063716.md) | [9.6](/filings/0001662774-25-000012.md) | [9.8](/filings/0000950170-24-058201.md) | [10.3](/filings/0001662774-24-000005.md) | [5.4](/filings/0001662774-24-000011.md) | [7.3](/filings/0001193125-26-151364.md) | [8.4](/filings/0001662774-25-000032.md) | [7.5](/filings/0000950170-25-106535.md) | [26.0](/filings/0001193125-25-277529.md) | [43.2](/filings/0001193125-26-352201.md) | [8.8](/filings/0001193125-26-217098.md) | [8.5](/filings/0001193125-26-352201.md) |
| Total liabilities | $m | [2.3](/filings/0000950170-23-063716.md) | [82.8](/filings/0001662774-25-000012.md) | [85.1](/filings/0000950170-24-058201.md) | [87.9](/filings/0001662774-24-000005.md) | [81.6](/filings/0001662774-24-000011.md) | [84.3](/filings/0001193125-26-151364.md) | [88.5](/filings/0001662774-25-000032.md) | [105](/filings/0000950170-25-106535.md) | [109](/filings/0001193125-25-277529.md) | [129](/filings/0001193125-26-352201.md) | [11.0](/filings/0001193125-26-217098.md) | [15.5](/filings/0001193125-26-352201.md) |
| Long-term debt | $m | not reported | [13.4](/filings/0001662774-25-000012.md) | [13.5](/filings/0000950170-24-058201.md) | [13.8](/filings/0001662774-24-000005.md) | [14.9](/filings/0001662774-24-000011.md) | [14.3](/filings/0001193125-26-151364.md) | [15.3](/filings/0001662774-25-000032.md) | [17.0](/filings/0000950170-25-106535.md) | [0.0](/filings/0001193125-25-277529.md) | [0.0](/filings/0001193125-26-151364.md) | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001193125-26-151364.md) | not reported | not reported | [17.5](/filings/0001193125-25-277529.md) | [18.0](/filings/0001193125-26-352201.md) | [0.0](/filings/0001193125-26-217098.md) | [0.0](/filings/0001193125-26-352201.md) |
| Shareholders' equity | $m | [83.1](/filings/0001662774-24-000011.md) | [85.1](/filings/0001193125-26-151364.md) | [74.2](/filings/0000950170-25-106535.md) | [47.0](/filings/0001193125-25-277529.md) | [44.9](/filings/0001193125-25-277529.md) | [30.1](/filings/0001193125-26-352201.md) | [18.6](/filings/0001193125-26-352201.md) | [11.7](/filings/0001193125-26-352201.md) | [1.1](/filings/0001193125-25-277529.md) | [(35.7)](/filings/0001193125-26-352201.md) | [15.7](/filings/0001193125-26-352201.md) | [(35.3)](/filings/0001193125-26-352201.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(4.8) d](/filings/0001662774-24-000011.md) | [(6.1) d](/filings/0001662774-25-000012.md) | [(8.4)](/filings/0001662774-25-000032.md) | [(8.7) d](/filings/0000950170-25-106535.md) | [(7.3) d](/filings/0001193125-25-277529.md) | [(7.6) d](/filings/0001193125-26-151364.md) | [(9.6)](/filings/0001193125-26-217098.md) | [(11.4) d](/filings/0001193125-26-352201.md) | [(9.9) d](/filings/0001193125-25-277529.md) | [(10.5) d](/filings/0001193125-26-151364.md) | [(7.6)](/filings/0001193125-26-217098.md) | [(18.9) d](/filings/0001193125-26-352201.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001662774-24-000011.md) | [0.0 d](/filings/0001662774-25-000012.md) | [0.0](/filings/0001662774-25-000032.md) | [0.0 d](/filings/0000950170-25-106535.md) | [0.0 d](/filings/0001193125-25-277529.md) | [0.1 d](/filings/0001193125-26-151364.md) | [0.1](/filings/0001193125-26-217098.md) | [0.1 d](/filings/0001193125-26-352201.md) | [0.1 d](/filings/0001193125-25-277529.md) | [0.0 d](/filings/0001193125-26-151364.md) | [0.0](/filings/0001193125-26-217098.md) | [0.0 d](/filings/0001193125-26-352201.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [35.6](/filings/0000950170-23-063716.md) | [35.9](/filings/0000950170-24-058201.md) | [35.9](/filings/0001662774-24-000005.md) | [36.1](/filings/0001662774-24-000011.md) | [43.0](/filings/0001662774-25-000032.md) | [43.1](/filings/0000950170-25-106535.md) | [43.2](/filings/0001193125-25-277529.md) | [4.4](/filings/0001193125-26-217098.md) | [0.2](/filings/0001193125-26-352201.md) | [54.0](/filings/0001193125-25-277529.md) | [9.2](/filings/0001193125-26-217098.md) | [6.1](/filings/0001193125-26-352201.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 1,017,063 at 2026-08-07, from the cover of the [10-Q filed 2026-08-14](/filings/0001193125-26-352201.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.